Drug intelligence / Profile preview

OV4041

Development stage: Preclinical
Lead developer: Ovid Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

OV4041 is an oral small-molecule direct activator of the potassium-chloride cotransporter 2 (KCC2) being developed by Ovid Therapeutics. KCC2 is a neuron-specific chloride transporter that maintains inhibitory balance in the brain and plays a central role in regulating neuronal excitability. By restoring chloride homeostasis and reducing neuronal hyperexcitability, OV4041 is intended to treat neurological and neuropsychiatric disorders where excitatory/inhibitory imbalance is a key driver. It is currently in preclinical development for the treatment of generalized anxiety disorder and Rett syndrome.

Targets

KCC2 (Potassium-chloride cotransporter 2)

Beyond the preview

Go deeper on OV4041.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OV4041.

Explore the full profile